A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer
Status:
Terminated
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of drugs as a possible treatment for
castration-resistant prostate cancer.
The interventions involved in this study are:
- Docetaxel (a type of chemotherapy)
- Apalutamide (the study medication, also known as ARN-509)
- Prednisone (a corticosteroid given to prevent reactions to docetaxel).
- Leuprolide acetate (also known as Lupron, a GnRH agonist or similar drug which is
standard of care, causes chemical castration which greatly lowers the level of
testosterone in the body)